- Home
- NSSC vs RCKT Comparison
NSSC vs RCKT Comparison
Compare NSSC & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSSC | RCKT |
|---|---|---|
| Founded | 1969 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 340.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NSSC | RCKT |
|---|---|---|
| Price | $40.98 | $3.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $47.50 | $29.12 |
| AVG Volume (30 Days) | 336.3K | ★ 2.0M |
| Earning Date | 02-02-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.23 | N/A |
| Revenue | ★ $186,786,000.00 | N/A |
| Revenue This Year | $13.13 | N/A |
| Revenue Next Year | $9.55 | N/A |
| P/E Ratio | $34.30 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.00 | $2.19 |
| 52 Week High | $48.12 | $13.30 |
Technical Indicators
Market Signals| Indicator | NSSC | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 65.39 |
| Support Level | $40.57 | $3.36 |
| Resistance Level | $42.21 | $3.64 |
| Average True Range (ATR) | 1.12 | 0.20 |
| MACD | -0.15 | 0.03 |
| Stochastic Oscillator | 13.21 | 82.56 |
Price Performance
Historical ComparisonAbout NSSC NAPCO Security Technologies Inc.
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.